MedImpact Selects Translational Software to Launch a Pharmacogenetics Program to Personalize Formularies Ending "Trial and Error" Prescribing for their Members
Summary
MedImpact, can now provide plan members a first-of-its-kind pharmacogenomics solution that systematically reviews every prescribed drug for a patient against a patient’s genetic profile. “The PBM industry has traditionally approached healthcare in terms of populations,’” said Karen Geary, MedImpact Vice President of Strategy and Innovation. “We excited to announce our partnership with MedImpact, as it aligns with our broader vision of continuing to democratize precision medicine and specifically pharmacogenetics,” said Don Rule, CEO of Translational Software. “Where many PGx programs subject clinicians to novel workflows that struggle to gain acceptance, the MedImpact model integrates seamlessly into their existing process. Translational Softwares pharmacogenomic knowledge base and Fast Healthcare Interoperability Resource (FHIR)-based API have been used to provide PGx recommendations for over one million patients.
Classifications
AskAI Classifications
LabelsLinked Companies
